The increased IGF-1 SDS was associated with a decreased probability of metabolic syndrome (OR 0.555, 95 % CI 0.385–0.801; P = 0.002) and hypertriglyceridemia (OR 0.582, 95 % CI 0.395–0.856; P = 0.006), but with no significant correlation with hypertension (OR 0.765, 95 % CI 0.567–1.031; P = 0.079). Here, IGF1 is linked to hypertensive disorder.